Table 2.

Emerging drug combinations with proteasome inhibitors for the treatment of multiple myeloma.

PI	Synergistic Partner	Signaling Pathway *	Main Target	Phase/Stage	Reference
bortezomib	CC-292	Tyrosine kinase	BTK	cell lines, mouse MM model, primary samples	[96]
bortezomib	everolimus	PI3K/AKT/mTOR	FKBP12	cell lines, mouse MM model	[97]
	pp242		mTORC1 and 2	cell lines	[98]
carfilzomib	montelukast		mTOR pathway	cell lines, mouse MM model, primary samples	[99]
	copanlisib		PI3Kα, PI3Kδ	cell lines, primary samples	[100]
	TGR-1202		PI3Kδ	cell line	[101]
	TAS-117		AKT	cell lines, mouse MM model, primary samples	[102]
bortezomib	enzastaurin		PKC	cell lines, mouse MM model, primary samples	[103]
multiple	THZ1	Cell cycle	CDK7	cell lines, mouse MM model, primary samples	[104]
bortezomib	CASIN		Cdc42	cell lines, mouse MM model, primary samples	[105]
multiple	LU-102	Stress	β2-PI	cell lines	[106]
bortezomib	WRR139		NGLY	cell lines	[107]
	bafilomycin A1		Vacuolar ATPase	cell lines	[108]
	verapamil		calcium channel	cell lines	[109]
	metformin		GRP78	cell lines, mouse MM models, primary samples	[110]
bortezomib	K145	Metabolism	SK2	cell lines, mouse MM models	[111]
carfilzomib	AGI-6780		IDH2	cell lines, mouse MM models, primary samples	[42]
bortezomib	STF-31		GLUT1	cell lines	[112]
multiple	compound C		AMPK	cell lines	[113]
carfilzomib	CB-839		Glutaminase	cell lines	[114]
multiple	E61		PDI	cell lines, mouse MM model	[115]
bortezomib	L-asparaginase		Asn, Gln	cell lines, mouse MM models, primary samples	[116]
	FK866		NAD+	cell lines, mouse MM model	[117]
bortezomib	EDO-S101	Epigenetics	HDACs	cell lines, mouse MM models, primary samples	[118]
	MPT0G413		HDAC6	cell lines, mouse MM models	[119]
	nexturastat A		HDAC6	cell lines, mouse MM models	[120]
	tubacin		HDAC6	cell lines, primary samples	[121]
	WT161		HDAC6	cell lines, mouse MM models, primary sample	[121]
	belinostat		HDACs	cell lines, primary samples, osteloclast	[122]
	CPI203		BET	cell lines, primary samples	[123]
	JQ-1		BET	cell lines, mouse CRC models	[124]
	UNC1999		EZH1/EZH2	cell lines, mouse MM models, primary samples	[125]
	decitabine		DNMT	cell lines	[126]
	5-Azacytidine		DNMT	cell lines, primary samples	[127]
bortezomib	BC2059	Wnt/β catenin	β catenin	cell lines, primary samples	[128]

* Designated pathway is targeted by synergistic partner. PI- proteasome inihibitor